福森有业 福 森 藥 業 有 限 公 司 FUSEN PHARMACEUTICAL COMPANY LIMITED (於開曼群島註冊成立的有限公司) 股份代號 : 1652 中 期 報 告 20 k 目錄 公司資料2 | --- | --- | |-------------------------------------|-------| | | | | 管 理 層 討 論 及 分 析 | | | 權 益 披 露 | | | 企 業 管 治 及 其 他 資 料 | | | 審 閱 報 告 | | | 綜 合 損 益 及 其 他 全 面 收 益 表 | | | 綜 合 財 務 狀 況 表 | | | 綜 合 權 益 變 動 表 | | | 簡 明 綜 合 現 金 流 量 表 | | | 未 經 審 核 中 期 財 務 報 告 附 註 | | | | | 公司資料 獨立非執行董事 提名委員會 公司秘書 王迪民先生 執行董事 曹長城先生(主席) 曹智銘先生 侯太生先生 孟慶芬女士 婴永勝先生 施永進先生 李國棟先生 杜潔華博士 審核委員會 施永進先生(主席) 李國棟先生 杜潔華博士 曹長城先生(主席) 李國棟先生 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 Fusen Pharmaceutical Company Limited 福森藥業有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1652） 截 至2024年6月30日 止 六 個 月 的 中 期 業 績 公 告 福 森 藥 業 有 限 公 司（「本 公 司」）董 事 會（「董 事 會」）在 此 公 佈 本 公 司 及 其 附 屬 公 司 截 至2024年6月30日 止 六 個 月 之 未 經 審 核 中 期 業 績 連 同2023年 同 期 的 比 較 數 字。 | --- | |------------------------------------------------------------------- ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 2023年度企業管治報告的 補充公告 背景 於 2020 年3 月 23 日 ，本 公 司宣 佈未 能 就向 實體 墊款 、 須予 披露 交 易及 關連 交 易遵 守報告、公告、通函及獨立股東批准規定，涉及由本公司全資附屬公司河南福森 藥業有限 公司（「河南福森」）於2019年3 月至2019 年11月分 批向淅川縣福森 中藥材 種植開發有限公司（「福森中藥材」）提供若干墊款（「墊款」），構成本公司未有遵守 上市規則第13.13、13.14、14.34、14A .35、14A .36及14A .46 條及其在上市規則第 3A .23條項下的披露責任。 此外，本公司未有及時披露有關河南福森於2020年1月至2020年2月期間向福森中 藥 材 支 付 的 兩 筆 款 項（「 付 款 」）的 關 連 交 易 ， 構 成 其 未 有 遵 守 上 ...

自薪酬委員會成立起直至本報告日期止,其進行的工作包括以下事項： 就執行董事的薪酬整定政策、評估執行董事的表現及批准執行董事服務合約的條款,及 薪酬委員會已採納企業管治守則的守則條文第 E.1.2(c)(ii)條所載的方式,就個別執行董事及高級管理層 的薪酬待遇向董事會提出推薦建議。 截至2023年12月31日止年度出席會議的次數 | --- | --- | --- | --- | --- | --- | |----------------|--------|------------|------------|------------|----------| | | 董事會 | 審核委員會 | 薪酬委員會 | 提名委員會 | 股東大會 | | | | | | | | | 執行董事 | | | | | | | 曹長城先生 | 4/4 | - | 2/2 | 1/1 | 1/1 | | 曹智銘先生 | 4/4 | - | - | - | 1/1 | | 侯太生先生 | 4/4 | - | - | - | 1/1 | | 孟慶芬女士 | 4/4 | - | - | - | 1/1 | | 遲永勝先生 | 4/4 | ...

| --- | --- | --- | |-------------------------------------------------------------|--------------|-----------------| | | | | | | | | | | | | | | 2023 年 千 | 2022 年 千 股 | | | 股 | | | | | | | 於 1 月 1 日 的 已 發 行 普 通 股 | 758,439 | 769,934 | | 購 回 股 份 的 影 響 | (6,383) | (13,860) | | | | | | 於 12 月 31 日 的 普 通 股 加 權 平 均 數 | 752,056 | 756,074 | (b) 每 股 攤 薄 虧 損 截 至2023年 及2022年12月31日 止 年 度 的 每 股 攤 薄 虧 損 並 無 計 及 尚 未 行 使 購 股 權 的 影 響，原 因 為 將 其 納 入 會 減 少 每 股 虧 損，因 此 具 有 反 攤 薄 作 用。 8 股 息 (a) 應 佔 年 內 應 付 本 公 司 股 權 持 有 人 的 股 息 ...

的受限制股份 6. 授歯日期 0.66% 中期赣告2023 的收市價 董事認可在本集團管理架構及內部監控程序內引入良好企業管治元素的重要性·藉以建致有效的問責制。 福森药业 中 期 報 告 目錄 01 中期報告2023 福森藥業有限公司 權益披露 12 審閱報告 20 綜合財務狀況表 23 簡明綜合現金流量表 26 27 公司資料 福荣蔬炭有限公司 主要往來銀行 永隆銀行有限公司 香港 德贛道中 45 號 股份資料 上市日期：2018年7月11日 註冊成立地點：開曼群島 上市地點：香港聯合交易所有限公司主板 股份代號：1652 買賣單位：1000股股份 財政年度結算日：12月31日 中期報告2023 業務回顧及未來展望 福安施燃布腺公司 福 森 藥 業 有 限 公 司 FUSEN PHARMACEUTICAL COMPANY LIMITED (於開曼群島註冊成立的有限公司) 股份代號：1652 2023 公司資料 2 管理層討論及分析 4 企業管治及其他資料 18 綜合損益及其他全面收益表 21 綜合權益變動表 25 未經審核中期財務報告附註 27 01 | --- | --- | --- | --- | - ...

截 至2023年6月30日 止 六 個 月 的 中 期 業 績 公 告 | --- | |-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | 財 經 摘 要 | | — 收 益 由 2022 年 上 半 年 約 人 民 幣 165.6 百 萬 元 增 加 約 103.1% 至 2023 半 年 約 人 民 幣 336.4 百 萬 元。 | | — 毛 利 由 2022 年 上 半 年 約 人 民 幣 79.7 百 萬 元 上 升 約 124.7% 至 2023 半 年 約 人 民 幣 179.1 百 萬 元。 | | — 於 2023 年 上 半 年，本 公 司 股 權 持 有 人 應 佔 溢 利 為 約 人 民 幣 16 ...

Revenue and Sales Performance - Revenue increased by 27.5% from RMB 385.7 million in 2021 to RMB 491.8 million in 2022[13] - Sales of Shuanghuanglian Oral Liquid grew by 6.1% to RMB 236.394 million, accounting for 48.1% of total revenue[13] - Sales of Shuanghuanglian Injection surged by 112.5% to RMB 73.864 million, representing 15.0% of total revenue[13] - Sales of Compound Ferrous Sulfate Granules decreased by 4.5% to RMB 20.682 million, accounting for 4.2% of total revenue[13] - Sales of other products increased by 36.4% to RMB 116.954 million, representing 23.8% of total revenue[13] - The company's product "Nifedipine Hydrochloride Injection" achieved sales revenue exceeding RMB 18.9 million in 2022[29] Cost and Profit Analysis - Cost of sales increased by 52.8% from RMB 174.5 million in 2021 to RMB 266.7 million in 2022[13] - The company's gross profit increased by RMB 13.9 million to RMB 225.0 million in 2022, with a gross profit margin of 45.8%, down 8.9% from 2021 due to increased depreciation and raw material procurement costs[40] - Income tax expense decreased from RMB 7.2 million in 2021 to RMB 3.7 million in 2022, primarily due to a decrease in taxable profit[24] - The company's net financing costs increased from RMB 7.1 million in 2021 to RMB 15.7 million in 2022, mainly due to increased foreign exchange losses and bank loan interest[41] Product and Market Strategy - Jiangxi Yongfeng Kant's core product Kaifuding sales are expected to recover this year[12] - The company plans to establish a chemical raw material production base this year to enhance cost competitiveness for future products participating in national centralized procurement[29] - The company expects to add 5 to 10 new product projects in 2023, focusing on chemical drugs and traditional Chinese medicine[29] - The company plans to expand into blank market regions by increasing sales personnel and distributors[29] - The company's product portfolio covers various therapeutic areas including heat-clearing and detoxifying, cardiovascular, antihypertensive and hypoglycemic, tonic, qi-regulating, anti-anemia, and anti-inflammatory. Notably, the heat-clearing product Shuanghuanglian Oral Liquid and Shuanghuanglian Injection have consistently ranked among the top three in national sales for similar products for many years[163] - The cardiovascular product Yansuan Fugui Liqin Capsule is the first generic product in China and has maintained the top sales position in the domestic market for five consecutive years[163] R&D and Innovation - The company's subsidiary, Jiaheng Pharmaceutical, will have its R&D laboratory operational in the second quarter of this year, with plans to expand the R&D team[29] - The company's R&D capabilities were strengthened in 2013 under the leadership of Executive Director Meng Qingfen, who was appointed to lead the R&D team[153] - The company has established Fosen (Shenzhen) Biopharmaceutical R&D Co., Ltd. and Fosen (Macau) Co., Ltd. as R&D centers for the development of innovative drugs, aiming to enhance R&D capabilities and expand the product portfolio[163] - The company adheres to the development strategy of "combining Chinese and Western medicine, long-term and short-term, and imitation and innovation," and follows the path of "producing one generation, reserving one generation, and researching and creating one generation" for new drug development[163] Financial Position and Liabilities - As of December 31, 2022, the company had a net current liability of approximately RMB 108.0 million (compared to a net current asset of RMB 20.0 million in 2021) and cash and cash equivalents of approximately RMB 128.1 million (compared to RMB 81.1 million in 2021)[43] - The company's total equity attributable to shareholders was approximately RMB 614.2 million as of December 31, 2022 (compared to RMB 658.2 million in 2021), with total debt of approximately RMB 225.8 million (compared to RMB 236.9 million in 2021)[43] - Capital commitments not provided for in the financial statements as of December 31, 2022, amounted to RMB 17,634 thousand, a significant increase from RMB 1,819 thousand in 2021[44] - The company's total equity attributable to shareholders as of December 31, 2022, was approximately RMB 612.9 million, down from RMB 656.9 million in 2021[90] - Total liabilities as of December 31, 2022, were approximately RMB 737.4 million, compared to RMB 582.4 million in 2021[90] Employee and Workforce Management - The company's employee turnover rate was 2.3% in 2022, indicating high employee stability[33] - The company's male employee turnover rate was 1.2% in 2022, while the female employee turnover rate was 1.1%[34] - The company's workforce as of December 31, 2022, consisted of 50.91% female and 49.09% male employees, reflecting the company's commitment to gender diversity[53] - In 2022, the number of male employees receiving training increased to 569, while female employees receiving training increased to 590, with both genders receiving 48 hours of training[103] - The company strictly adheres to labor standards, prohibiting child labor and forced labor, and ensures compliance with labor laws and regulations[105] - The company implemented a paid leave system starting in 2011 and ensures overtime compensation for employees[105] - The company provides competitive employee benefits, including housing subsidies, tuition subsidies, and equity incentives[82] - The company conducted regular employee forums, team-building activities, and communication mechanisms to enhance internal collaboration and employee engagement[99] Environmental, Social, and Governance (ESG) - The company is installing photovoltaic solar panels on existing factory roofs to reduce electricity costs and carbon emissions[30] - The company has increased its efforts in environmental, social, and governance (ESG) practices and disclosures, compiling the "2022 ESG Report" and initiating the formulation of ESG management policies and strategies[175] - The company established a three-level environmental management network led by the general manager, ensuring environmental management decisions and systems are implemented at all levels[176] - In September 2022, the company publicly released an environmental commitment letter, pledging to comply with environmental laws and regulations and take full responsibility for environmental protection[178] - The company installed pollution control devices at all exhaust outlets, ensuring emissions meet standards and do not affect surrounding residents[179] - Solid waste is strictly classified and disposed of according to legal requirements, minimizing waste generation and environmental pollution[181] - The company plans to establish an ESG management committee in 2023 to oversee ESG goals, risk assessments, and sustainable development initiatives[186] - Wastewater is treated at the plant's sewage treatment station and discharged into the municipal sewage network, ensuring no negative impact on the surrounding water environment[189] - Electricity consumption in 2022 was 7,542,243 kWh, a significant increase from 2,850,300 kWh in 2021[197] - Natural gas consumption in 2022 was 2,571,470 cubic meters, up from 1,045,940 cubic meters in 2021[197] - The company emphasizes water conservation through recycling processes, strict water usage plans, and employee education to reduce water waste[198] - The company focuses on reducing packaging materials, including glass, plastic, paper, PVC, and aluminum foil, in product design[200] Corporate Governance and Compliance - The company's board of directors consists of eight members, including three independent non-executive directors, with six male and two female directors, demonstrating diversity in gender, age, education, and professional experience[52] - The board of directors held six meetings, the audit committee held four meetings, the remuneration committee held two meetings, and the nomination committee held one meeting during the year ended December 31, 2022[75] - The company established a Remuneration Committee on June 14, 2018, consisting of two independent non-executive directors and one executive director, responsible for recommending compensation policies and structures for directors and senior management[97] - The Remuneration Committee reviewed the company's compensation policies and structures for all directors and senior management since its establishment[98] - The company's external auditor, KPMG, was paid RMB 3,900 thousand for audit services in 2022[59] - No significant contingent liabilities were reported as of December 31, 2022[87] - The company maintains a strong liquidity position to capitalize on future growth opportunities[89] Supplier and Procurement Management - The company has 54 suppliers and adheres to strict supplier selection and evaluation processes in compliance with pharmaceutical regulations[117] - The company's procurement policy ensures that prices paid to Fosen Traditional Chinese Medicine are not higher than those offered by independent suppliers and are in line with market rates[81] - The company has a strict supplier management system, including a two-year comprehensive evaluation of suppliers based on factors such as product quality, delivery timeliness, and credit terms[131] - The company has a total of 54 suppliers across different regions, with the highest number (25) in the Central Plains region[130] - The annual procurement limit for Fosen Da Health was approximately RMB 12.9 million in 2022, within the range of the annual cap of RMB 15.0 million, RMB 17.0 million, and RMB 19.0 million for the three years ending December 31, 2023[45] - The annual procurement limit from Fosen Traditional Chinese Medicine for the years 2023, 2024, and 2025 is approximately RMB 40.0 million, RMB 44.0 million, and RMB 48.0 million, respectively[77] - The packaging material procurement agreement with Furen Health constitutes a continuing connected transaction under the listing rules, with all applicable percentage ratios exceeding 0.1% but below 5%[73] - If the price offered by Furen Health is inferior to that of independent suppliers, Henan Furen will not enter into transactions with Furen Health[72] - The company has a policy to review pricing every six months, and individual agreements or orders will be entered into with Furen Chinese Herbal Medicine for the purchase of herbs[71] Quality Assurance and Control - The company has maintained a 0% product return rate for the past three years (2020-2022)[135] - The company received 12 product complaints in 2022, an increase from 4 in 2021[144] - The company has a robust quality assurance system in place, adhering to GMP standards and conducting regular self-inspections[134][142] - The company has established a GAP planting base for Chinese medicinal materials to ensure product quality from the source[141] - The company has established a "Medical Consultation and Complaint Handling Procedure" to address user feedback on product quality, including non-clinical issues (e.g., packaging changes, minor damage) and severe adverse reactions affecting user health, managed by the Drug Safety Office Director[146] - The company established a Quality Control system with detailed procedures for material testing, product inspection, and quality risk management[113] - The company has formulated the "Quality Objective Management Regulations" to achieve quality policies and objectives, and established a "Quality Assurance System" and "Quality Control System" to ensure product and service quality[161] Shareholder and Equity Management - Two grantees were each awarded 2,500,000 restricted share units, with vesting conditions tied to business development performance metrics, including the number of business partners introduced and the successful launch of products[63] - The number of restricted share units (RSUs) available for grant under the RSU plan as of December 31, 2022, was 71,993,400 units[64] - The maximum number of shares that can be granted to each eligible person under the RSU plan and any other share plans of the company within any 12-month period is 1% of the total issued shares[64] - The RSU plan will be effective for ten years from the date of the first grant, subject to early termination by the board[67] - The weighted average number of shares issued or potentially issuable under all plans as of December 31, 2022, was 0.66% of the total issued shares[67] Operational Challenges and Achievements - In 2022, the company faced challenges due to the normalization of sporadic COVID-19 outbreaks, which led to restrictions or bans on the sale of cold, fever, and cough medicines in various regions, impacting business operations[175] - Despite challenges, the company completed the relocation and expansion of production facilities and related health industry construction in 2022, significantly improving production processes and management levels[175] - The company integrates social service into its corporate culture, strategic policies, and daily operations, actively practicing the concept of "health is happiness" and striving to be a leader in the health industry[175] Related Party Transactions - Furen Pharmaceutical Group's related party, Furen Chinese Herbal Medicine, is wholly owned by Furen Industrial Group, which is 35.08% owned by the company's executive director and chairman, Mr. Cao Changcheng[70] - The company's share of losses from a joint venture increased by approximately RMB 23.5 million, from a profit of RMB 11.7 million in 2021 to a loss of RMB 11.8 million in 2022, primarily due to a decline in sales of the main product, Kaifuding, and inventory write-downs[42] Employee Costs and Benefits - In 2022, the company's total employee costs, including directors' remuneration, retirement plan contributions, bonuses, and other benefits, amounted to approximately RMB 91.8 million, up from RMB 75.6 million in 2021[88] - As of December 31, 2022, the company had 1,159 employees, a decrease from 1,243 employees in 2021[88] Other Income and Expenses - Other income net increased by RMB 10.2 million from a net loss of RMB 2.8 million in 2021 to a net income of RMB 7.4 million in 2022[14] - General and administrative expenses increased by 7.2% from RMB 65.2 million in 2021 to RMB 69.9 million in 2022, mainly due to increased R&D costs[22] Risk Management and Compliance - The company has established a cross-currency swap contract to mitigate the impact of foreign exchange risk from USD-denominated bank loans[121] - No significant acquisitions or disposals were made during the year ended December 31, 2022[122] - No significant investments were made during the year ended December 31, 2022, apart from those disclosed in the report[123] - No significant events occurred after December 31, 2022, that would materially affect the company's operations and financial performance[124] Employee Development and Training - The company has established a "mentorship" mechanism, theoretical training mechanism, platform practice mechanism, and joint training mechanism to enhance the professional capabilities and management levels of various personnel[74] - The company promotes labor union development and ensures employee participation in major decisions through employee representative meetings[115] - The company maintains a transparent and democratic management system, with regular employee feedback collection and implementation of reasonable suggestions[115]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容 概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對 因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 Fusen Pharmaceutical Company Limited 福 森 藥 業 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1652） 截 至2022年12月31日 止 年 度 的 年 度 業 績 公 告 財務摘要 • 截至2022年12月31日止年度的收益約為人民幣491.8百萬元，較截至 2021年12月31日止年度約人民幣385.7百萬元增加約27.5%。 • 毛利由截至2021年12月31日止年度約人民幣211.1百萬元增加約6.6% 至截至2022年12月31日止年度約人民幣225.0百萬元。 • 截至2022年12月31日止年度的毛利率約為45.8%，較截至2021年12月 31日止年度約54.7%減少約8.9%。 • 截 至2022年12月31日 止 年 度 的 本 公 司 股 權 持 有 人 應 佔 虧 損 約 為 人 ...

唯 复方硫酸亚铁颗粒 p 【黄连口服液 本 188 WO 5100XX 点 小儿咳喘灵口服液 " 盐酸氟桂利購胶囊 通 脉 □ 服 液 4 盐酸尼卡地平注射液 A, MOTOR 只是王永》又土壤线, 允许 比春歌化, 图曲家, 第四五 r O ■ケイ and Property - 双黄连口服液 元胡止痛口服液 双黄连口服液 o 2 06 f� 告 期 報 E 器药业 福 森 藥 業 有 限 公 司 FUSEN PHARMACEUTICAL COMPANY LIMITED (於開曼群島註冊成立的有限公司) 股份代號 : 1652 -flog 复方硫酸亚铁颗粒 - 2 品就具左利波数量 盐酸尼卡地平注射液 = 雷波国 | --- | --- | |---------------------------|-------| | | | | 公司资料 | 2 | | 管理層討論及分析 | 4 | | 權益披露 | 11 | | 企業管治及其他资料 | 14 | | 審閱報告 | 17 | | 綜合損益及其他全面收益表 | 18 | | 綜合財務狀況表 | 20 | | 綜合權益變動表 | 22 | | 簡明綜合現金流量 ...